TGFB1 and neoplasm: In contrast to single-agent treatment, the combination therapy of anti-TGFβ and anti-PD-L1 antibodies led to an improved overall response rate in KPP-eGFP STAMP tumours (Fig. 4b and Extended Data Fig. 9b–d).